KDR and neoplasm: Sorafenib is a multitargeted tyrosine kinase inhibitor that blocks the Ser/Thr kinase Raf and several receptor tyrosine kinases including VEGFR-2 and -3 and PDGFR-β to inhibit tumor cell proliferation and tumor angiogenesis.